Loading
Life sciences · Journal article
Adolescencia E Saude · August 1, 2026
Raises a question worth testing. It does not answer one.
This is a narrative review of Paris polyphylla, a traditional Chinese medicinal herb, summarising published reports of its phytochemical constituents and in vitro or preclinical pharmacological activities. The review documents historical and traditional uses alongside laboratory evidence of anti-tumour, anti-inflammatory, antioxidant, antimicrobial, and neuroprotective effects, but contains no clinical trials, human efficacy data, or safety assessments to support therapeutic claims.
Narrative review.
Polyphyllins I, II, VI, VII, and Polyphyllin H have demonstrated strong anti-tumour activities against hepatocellular carcinoma, osteosarcomas, glioma, lung cancer, breast cancer, chronic myelogenous leukaemia, ovarian cancer, colorectal cancer, and gastric cancer Paris polyphylla rhizome has been historically used to treat skin allergies, tumours, pain, fungal illnesses, bleeding, and snake bites Paris saponins or steroidal saponins are identified as the main bioactive chemical constituents
No safety, toxicity, or adverse event data provided No quantitative effect sizes, confidence intervals, or p-values for pharmacological claims
The source did not state who this applies to in practice.
This is a narrative review of traditional uses and preclinical pharmacology without clinical trials, randomised comparisons, or human efficacy data; it raises questions about potential therapeutic applications rather than answering them.
As stated by the source record.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Background: Paris polyphylla Smith.(chonglou) is an important traditional Chinese medicinal herb which has been used widely in the treatment of infectious and inflammatory diseases and cancer in China for thousands of years. The IUCN red list has designated it as "vulnerable" due to depletion of wild population by deforestation, habitat degradation and uncontrolled harvesting for local medicine. The rhizome of Paris polyphylla has historically been used to treat various diseases. including skin allergies, tumors, pain, fungal illnesses, bleeding, and snake bites. Paris saponins or steroidal saponins are the main bioactive chemical constituents from this plant which have demonstrated significant pharmacological effects in various diseases. Objective: The current review investigates how P. polyphylla functions to treat various disease conditions, while current scientific studies continue to expand its medicinal applications. The review further explores recent research findings in the medicinal properties of P. polyphylla and its integration into present healthcare systems. Method: This detailed review presents recent findings on P. polyphylla and explains how its numerous health benefits operate through various biological pathways. The study presents both traditional uses and current scientific research on its pharmacological properties. It also examines both the challenges and opportunities in P. polyphylla research, aiming to bridge traditional knowledge with modern scientific approaches in integrated medicine. Results: Polyphyllins I, II, VI, VII, and Polyphyllin H have demonstrated strong anti-tumor activities against various malignancies, including hepatocellular carcinoma, osteosarcomas, glioma, lung cancer, breast cancer, Chronic myelogenous leukaemia, ovarian cancer, colorecta cancer, and gastric cancer. Anti-inflammatory, antioxidant, antimicrobial, anti-gynecological disease, hemostatic, and neuroprotective effects have also been exhibited by the medicinal plant. Conclusion: This review summarizes the bioactive compounds from the P. polyphylla which will be of great value in the development of Polyphyllin products.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.